Gene therapy uses AAV vectors to deliver medicine directly to cells. However, many people naturally develop antibodies against these vectors. These antibodies can act like a shield, preventing the therapy from working or making it impossible for some patients to join clinical trials.
Research shows that the number of these antibodies tends to increase as people get older. This trend varies by region, but it poses a challenge for doctors trying to treat a wide range of patients. Because many trials have strict rules against patients with these antibodies, many people might be left out of treatment.
While the data is limited in some parts of the world, the findings suggest that we need better ways to manage these immune responses. Developing standard tests and new ways to calm the immune system could help more people qualify for and benefit from these life-changing therapies.
Common questions
What are AAV vectors and why do antibodies matter?
AAV vectors are used to deliver genes for medical treatment. Some people have natural antibodies against these vectors. These antibodies can block the therapy from working or prevent a person from joining a clinical trial because the body recognizes the vector as a threat.
Does age affect whether someone can receive gene therapy?
Yes, research shows that the number of antibodies against AAV vectors tends to increase as people get older. This means older patients might be more likely to have these antibodies, which could impact their eligibility for certain gene therapy treatments.
How many people usually join these gene therapy trials?
The data shows that the median number of participants in these trials was 14. Because many people have antibodies that disqualify them, finding enough eligible patients can be a challenge for researchers.
